A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). I was asked to discuss the topic on ...
Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...
A bipartisan group of senators are filing a bill that would force health insurers or PBMs to divest their pharmacy businesses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback